LNK in Polycystic Ovary Syndrome With Insulin Resistance

NCT05146063 | Unknown

• 1 other identifier: SYSEC-KY-KS-2021-187
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Insulin resistance (IR) is an important pathological feature of polycystic ovary syndrome (PCOS), with an incidence rate of up to 85%, which seriously affects the patient's fertility, quality of life, and offspring health, but the mechanism is unknown. The adaptor protein LNK is closely related to metabolic diseases. Our exome sequencing has found that the mutation rate of LNK gene in patients with PCOS and IR is high. Studies have found that LNK can affect adipose inflammation and impair glucose tolerance. Whether LNK is related to fat metabolism is worth further study. Our previous research found that: LNK expression was significantly increased in adipose tissue of patients with PCOS and IR. Knockout of LNK in PCOS IR model mice can reduce serum triglycerides, free fatty acids, high-sensitivity C-reactive protein levels and reduce fatty liver occurrence, which indicates that LNK has a mitigating effect on IR. Mechanism studies have shown that LNK knockout can upregulate the glucose transporter Glut4, also LNK and insulin receptor substrate IRS-1 can form protein complexes. Based on the above research basis, we propose the following scientific hypothesis: LNK in adipose tissue can regulate insulin signaling pathway by binding to IRS-1, downregulate Glut4, and participate in PCOS IR occurrence. This project intends to clarify the specific mechanism by which LNK regulates glucose transport and participate in IR in combination with clinical specimens, animal models and cell experiments, and provide scientific basis for LNK as a potential therapeutic target for PCOS IR.

Conditions

Polycystic Ovarian Syndrome; Insulin Resistance

Outcome Measures

Primary Outcomes (2)

• mRNA expression levels of LNK

  The expression level of LNK mRNA in the subcutaneous adipose tissue of the PCOS patients

  2 years

• protein expression levels of LNK

  The expression level of LNK protein in the subcutaneous adipose tissue of the PCOS patients

  2 years

Study Arms (2)

Polycystic ovary syndrome patients with insulin resistance

Diagnostic Test: Take the patient's subcutaneous fat tissue to detect the expression of LNK

Polycystic ovary syndrome patients without insulin resistance

Diagnostic Test: Take the patient's subcutaneous fat tissue to detect the expression of LNK

Interventions

Take the patient's subcutaneous fat tissue to detect the expression of LNK DIAGNOSTIC_TEST

Take the patient's subcutaneous fat tissue to detect the mRNA and protein expression levels of LNK by RT-qPCR and western blot.

Polycystic ovary syndrome patients with insulin resistance; Polycystic ovary syndrome patients without insulin resistance

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Patients with polycystic ovary syndrome who met the 2003 Rotterdam criteria were divided into insulin resistance group and non-insulin resistance group

You may qualify if:

• Patients with polycystic ovary syndrome who meet the 2003 Rotterdam criteria

You may not qualify if:

• Do not meet the diagnostic criteria for polycystic ovary syndrome

Sponsors & Collaborators

• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University: lead

Study Sites (1)

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, 510120, China

RECRUITING

MeSH Terms

Conditions

Polycystic Ovary Syndrome; Insulin Resistance

Condition Hierarchy (Ancestors)

Ovarian Cysts; Cysts; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Gonadal Disorders; Endocrine System Diseases; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Yi Zhang

  Sun Yat-sen Memorial Hospital, Sun Yat-sen Univers

  STUDY DIRECTOR

Central Study Contacts

Yi Zhang

CONTACT

+862081332120; sys_iit@163.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 11, 2021
• First Posted: December 6, 2021
• Study Start: November 5, 2021
• Primary Completion: December 31, 2022
• Study Completion: December 31, 2023
• Last Updated: December 6, 2021

Record last verified: 2021-11

Locations

CN (1)